Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...

Eli Lilly has delivered a jaw-dropping 635% stock price increase from 2020 to 2024, driven by high hopes and heavyweight drug ...